Loading financial data...

Protagonist Therapeutics, Inc (PTGX) Financial Statements | Global Financial Data

Protagonist Therapeutics, Inc

PTGXSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1377121

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Research and Development Expense	$120.2M	$126.2M	$126.0M	$74.5M	$65.0M
Operating Expenses	$153.7M	$158.0M	$153.2M	$93.1M	$80.8M
Operating Income (Loss)	-$93.7M	-$131.4M	-$125.8M	-$64.5M	-$80.5M
Interest Expense	—	—	—	$598.0K	$169.0K
Other Nonoperating Income (Expense)	-$201.0K	-$80.0K	-$149.0K	-$46.0K	-$1.0K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$79.0M	-$127.4M	-$125.6M	-$64.8M	-$77.9M
Income Tax Expense (Benefit)	$4.2M	$4.2M	$0.00	$1.3M	-$691.0K
Net Income (Loss) Attributable to Parent	-$79.0M	-$127.4M	-$125.6M	-$66.2M	-$77.2M
Earnings Per Share, Basic	-$1.39	-$2.60	-$2.71	-$1.92	—
Earnings Per Share, Diluted	-$1.39	-$2.60	-$2.71	-$1.92	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$744.7M	$358.0M	$247.9M	$347.7M	$324.5M
Assets, Current	$591.6M	$355.6M	$243.1M	$340.7M	$315.6M
Cash and Cash Equivalents, at Carrying Value	$186.7M	$125.7M	$123.7M	$117.4M	$33.0M
Liabilities	$69.4M	$21.3M	$32.3M	$47.7M	$44.9M
Liabilities, Current	$47.4M	$21.3M	$31.2M	$44.0M	$40.2M
Long-term Debt	—	—	—	—	—
Accounts Payable, Current	$1.6M	$772.0K	$3.6M	$1.6M	$3.1M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$70.2M	-$108.1M	-$107.9M	-$72.5M	-$41.5M
Net Cash Provided by (Used in) Investing Activities	-$39.3M	$91.5M	-$15.9M	-$91.0M	-$53.7M
Net Cash Provided by (Used in) Financing Activities	$170.5M	$18.8M	$129.9M	$247.6M	$46.0M
Payments to Acquire Property, Plant, and Equipment	$609.0K	$795.0K	$1.1M	$471.0K	$967.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)